Bile acids: the role of peroxisomes

Sacha Ferdinandusse,*, Simone Denis,* Phyllis L. Faust,† and Ronald J. A. Wanders*

Laboratory of Genetic Metabolic Diseases,* Academic Medical Center at the University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands and Department of Pathology and Cell Biology,† Columbia University, New York, NY

Abstract It is well established that peroxisomes play a crucial role in de novo bile acid synthesis. Studies in patients with a peroxisomal disorder have been indispensable for the elucidation of the precise role of peroxisomes. Several peroxisomal disorders are associated with distinct bile acid abnormalities and each disorder has a characteristic pattern of abnormal bile acids that accumulate, which is often used for diagnostic purposes. The patients have also been important for determining the pathophysiological consequences of defects in bile acid biosynthesis. In this review, we will discuss all the peroxisomal steps involved in bile acid synthesis and the bile acid abnormalities in patients with peroxisomal disorders. We will show the results of bile acid measurements in several tissues from patients, including brain, and we will discuss the toxicity and the pathological effects of the abnormal bile acids.—Ferdinandusse, S., S. Denis, P. L. Faust, and R. J. A. Wanders. Bile acids: the role of peroxisomes. J. Lipid Res. 2009. 50: 2139–2147.

Supplementary key words dihydroxycholestanoic acid • trihydroxycholestanic acid • peroxisome deficiency disorders • D-bifunctional protein deficiency • α-methylacyl-CoA racemase deficiency

THE BILE ACID BIOSYNTHESIS PATHWAY

The primary bile acids, cholic acid (CA) and chenodeoxycholic acid (CDCA), are formed from cholesterol by a sequence of enzymatic modifications involving several enzymes, multiple subcellular compartments, and two main pathways (see Ref. 1 for a detailed review on the bile acid biosynthesis pathway). The most important difference between the classic and alternative pathway is the order of reactions and the subcellular compartment where the first reaction takes place (endoplasmic reticulum vs. mitochondrion, respectively). The enzymes involved in the two pathways are the same except for those responsible for the hydroxylation of the steroid nucleus at the C-7 position. In the classic pathway, this reaction is performed by cholesterol 7α-hydroxylase (CYP7A1), whereas oxysterol 7α-hydroxylase (CYP7B1) is responsible for this hydroxylation in the alternative pathway. The biosynthesis pathway basically consists of modification of the steroid nucleus, oxidation of the sterol side chain, cleavage of the side chain, and finally, conjugation with an amino acid, either taurine or glycine. Microsomal and cytosolic enzymes modify the steroid nucleus. Oxidation of the sterol side chain occurs in the mitochondrion, and finally, both the cleavage of the side chain and subsequent conjugation take place in the peroxisome.

Oxidation of the sterol side chain results in formation of the C_{27}-bile acid intermediates 3α,7α-dihydroxycholestanic acid (DHCA) and 3α,7α,12α-trihydroxycholestanic acid (THCA). DHCA is the precursor of the primary C_{24}-bile acid CDCA and, when hydroxylated at C-12, the precursor of CA. THCA is the precursor of CA. The C_{24}-bile acids are formed from the C_{27}-bile acid intermediates by peroxisomal β-oxidation of the side chain (Fig. 1). Before this side chain can be shortened by β-oxidation, it has to be activated to a CoA-thioester and the C_{27}-bile acyl-CoA has to be transported into the peroxisome. To date, two enzymes have been identified that are capable of activating the C_{27}-bile acid intermediates. The first enzyme is the bile acyl-CoA synthetase (BACS, also called bile acid CoA ligase), which is liver-specific and located at the endoplasmic reticulum. It accepts both C_{27}- and C_{24}-bile acids as substrates (2, 3). The second enzyme

Downloaded from http://www.jlr.org/ on March 24, 2009

Manuscript received 24 March 2009 and in revised form 8 April 2009.
Published, JLR Papers in Press, April 2009
DOI 10.1194/jlr.R900009-JLR200

Copyright © 2009 by the American Society for Biochemistry and Molecular Biology, Inc.
This article is available online at http://www.jlr.org

Journal of Lipid Research Volume 50, 2009 2139

Abbreviations: AMACR, α-methylacyl-CoA racemase; BACS, bile acyl-CoA synthetase; BAAT, bile acyl-CoA: amino acid N-acyltransferase; BCOX, branched-chain acyl-CoA oxidase; CA, cholic acid; CDCA, chenodeoxycholic acid; DBP, D-bifunctional protein; DCA, deoxycholic acid; DHCA, dihydroxycholestanic acid; FXR, farnesoid X receptor; SCPx, sterol carrier protein X; THCA, trihydroxycholestanic acid; UDCA, ursodeoxycholic acid.

† To whom correspondence should be addressed.
e-mail: S.Ferdinandusse@amc.uva.nl
Fig. 1. Schematic representation of the peroxisomal steps involved in bile acid biosynthesis.
that has been shown to be capable of handling the C27-bile acid intermediates in expression studies is the very long-chain acyl-CoA synthetase (2). It is expressed primarily in liver and kidney and is located in both the endoplasmic reticulum and in the peroxisome. In addition to the C27 bile acid intermediates, the enzyme has been shown to handle C24:0, C16:0, phytic acid and pristanic acid as substrates, but is not capable of activating the primary C24 bile acids (2, 4). To date, formation of DHC-CoA and THCA has only been demonstrated at the endoplasmic reticulum and not in peroxisomes (5, 6). The kinetic properties of the THC-CoA synthetase and choloyl-CoA synthetase activities at the endoplasmic reticulum have been shown to be different (6), which suggests that both BACS and very long-chain acyl-CoA synthetase are involved in the activation of the C27 and C24 bile acids at the endoplasmic reticulum. In agreement with a microsomal, and not peroxisomal, activation of the C27-bile acid intermediates is the demonstration of ATP-dependent transport of THC-CoA into the peroxisome (7). THCA and THC-CoA were incubated with isolated rat liver peroxisomes and the products of peroxisomal β-oxidation were measured (7). The results of these experiments showed that THC-CoA is the preferred substrate for transport. However, it must be noted that peroxisomes isolated by differential centrifugation are leaky, which makes them not optimal for these kinds of experiments. For this reason, transport should ideally be studied by reconstitution of the transporter or peroxisomal membrane proteins in liposomes. The identity of the transporter for the C27-bile acyl-CoA’s is at this moment still unknown.

Once inside the peroxisome, the side chain of the C27 bile acid intermediates will be shortened via β-oxidation (Fig. 1). First racemisation of the methyl-group at C-25 will occur by the enzyme α-methylacyl-CoA racemase (AMACR) (8, 9). This is necessary because the first enzyme of the β-oxidation system, branched-chain acyl-CoA oxidase (BCOX), only accepts (S)-isomers as substrate (10, 11), whereas cholesterol 27-hydroxylase (CYP27A1), which forms the carboxyl-group at the side chain in the mitochondrion, only produces the (25R)-isomers of the C27 bile acid intermediates (12, 13). After racemisation, BCOX forms the 24-enoyl-CoA of THCA and DHCA (14). This is followed by a subsequent hydration and dehydrogenation reaction, both performed by D-bifunctional protein (DBP). DBP is also a stereospecific enzyme and only forms (24R)-OH (25R), -isomers, which it subsequently dehydrogenates into 24-keto-CoA-esters (15–18). Finally, sterol carrier protein X (SCPx) is responsible for the thiolic cleavage into propionyl-CoA and CA-CoA/CDC-CoA (19–21). A detailed description of the different β-oxidation steps has been reviewed previously (22).

The final step in de novo bile acid synthesis is the conjugation/amidation of the C27 bile acids to glycine or taurine. This reaction is performed by the enzyme bile acyl-CoA: amino acid Nacyltransferase (BAAT), which converts the bile acyl-CoAs into tauro- or glyco-bile acids, thereby releasing free CoA (23–25). This reaction occurs in the peroxisome, after which the conjugated C27 bile acids are transported out of the peroxisome and subsequently out of the hepatocyte and into the bile. Recently, bile acid transport activity has been detected and characterized by reconstitution of peroxisomal membrane proteins into liposomes; however, the identity of the transporter remains unknown (26). Conjugation of bile acids not only involves newly synthesized bile acids but also bile acids that have been deconjugated in the intestine and recycled via enterohepatic circulation (2). The deconjugated primary and secondary bile acids are reactivated to CoA thiosters at the cytosolic side of the endoplasmic reticulum by BACS (2); however, the question remains as to where they are reconjugated. By now, the peroxisomal localization of BAAT has been firmly established (25, 27, 28) but there is a longstanding dispute in the literature about a possible dual localization of BAAT, both in the peroxisome and in the cytosol (29–32). A cytosolic localization would negate the need for recycled bile acids to be transported back into the peroxisome just to undergo conjugation. For this reason, further research is needed to firmly establish the precise localization of BAAT.

### BILE ACID ABNORMALITIES IN PATIENTS WITH PEROXISOMAL DISORDERS

Investigation of the bile acid abnormalities in the various peroxisomal disorders has been of great value, not only for establishing that functional peroxisomes are necessary for bile acid biosynthesis, but also for determining which peroxisomal enzymes are involved in this pathway. Analysis of plasma from patients with a peroxisome deficiency disorder (i.e., Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease) reveals the presence of C27-bile acid intermediates but also a C29 dicarboxylic acid (33, 34). This dicarboxylic acid (3α,7α,12α-trihydroxy-27-carboxymethyl-5β-cholestane-26-oic acid) is thought to be formed by chain-elongation of THC-CoA (35, 36). The extent of the accumulation of bile acid intermediates has been shown to vary greatly and correlates with the extent to which peroxisomes are deficient (34). In urine of patients with a peroxisome deficiency disorder, the C27-bile acid intermediates are also present, but predominantly a tetrahydroxy-5β-cholestanolic acid and sometimes even pentahydroxy-5β-cholestanolic acid (37–39). Hydroxylation of THCA (of the steroid nucleus mainly at C-1 and C-6 but also of the side chain at C-24, C-25 or C-26) is an important mechanism for increasing the polarity and thereby, the urinary excretion of the C27 bile acid intermediates. In addition, bile alcohol glucuronides are present in urine, which are formed via an alternative pathway for bile acid biosynthesis not requiring the participation of peroxisomes, i.e., the microsomal 25-hydroxylase pathway. The C27 dicarboxylic acid is poorly excreted and for this reason it is not always present in urine.

The most striking bile acid abnormality in AMACR deficiency is the presence of only the (25R)-isomer of the C27 bile acid intermediates (40, 41). In contrast, in other
peroxisomal disorders with a defect in bile acid biosynthesis, both the (25R)- and (25S)-isomers accumulate. Just like in patients with a peroxisome deficiency disorder, many polyhydroxylated C₂₅ bile acids are present in urine (41).

To date, no patients with a deficiency of BCOX have been identified but the bile acid abnormalities will most likely resemble those of peroxisome deficiency disorders and AMACR deficiency, although the main accumulating isomer will be the (25S)-isomer in BCOX deficiency. The role of BCOX in the oxidation of bile acids has been established by in vitro studies with the purified enzyme (42, 43) and by the fact that patients with a deficiency of the other peroxisomal acyl-CoA oxidase (straight-chain acyl-CoA oxidase) do not have a bile acid biosynthesis defect (44).

The bile acid abnormalities in DBP deficiency are more complex because DBP displays two catalytic activities, resulting in multiple types of DBP deficiency. In addition, the other peroxisomal bifunctional enzyme, L-bifunctional protein, also displays activity with certain isomers of the C₂₅ bile acid intermediates. In all types of DBP deficiency, DHCA, THCA, and the direct substrate of DBP, the 24-enoyl of the C₂₅ bile acid intermediates are present in plasma (45, 46). The hydratase activity is deficient (DBP type I and II deficiency, i.e., combined deficiency of the hydratase and dehydrogenase activity and isolated hydratase deficiency, respectively) (24S)-OH (25S), -THC-CoA is also present, being formed by L-bifunctional protein. This isomer is not a substrate for any of the two peroxisomal dehydrogenases and cannot be metabolized further. When only the dehydratase activity is deficient (DBP type III deficiency), (24S), -OH (25S), -THC-CoA is also present, but the main accumulating metabolite is (24R)-OH (25R), -THC-CoA, which is formed by the hydratase unit of DBP (45, 46). A small portion is converted into (24R)-OH (25S), -THC-CoA by AMACR, which cannot be metabolized further (47). In urine, the presence of the taurine conjugate of hydroxylated 24-ene-THCA and dihydroxylated 24-ene-THCA is characteristic for patients with DBP deficiency (22). As for peroxisome deficiency disorders, the extent of the accumulation of the C₂₅ bile acid intermediates varies between patients and this seems to correlate with the extent of the deficiency of DBP. Bile acid abnormalities are not found in plasma in 26% of DBP-deficient patients (48).

In plasma of the only SCPx-deficient patient identified to date, only trace amounts of DHCA and THCA were present (49). However, large amounts of bile alcohol glucuronides were identified in urine. In addition, products formed by hydroxylation and decarboxylation of the SCPx substrate 3α,7α,12α-trihydroxy-24-keto-cholestanoyl-CoA were present, namely pentahydroxy-27-nor-5β-cholestan-24-one (m/z 611) and hexahydroxy-27-nor-5β-cholestan-24-one glucuronides (m/z 627).

Although the bile acid abnormalities in plasma and urine of patients with a peroxisomal fatty acid oxidation disorder have been well characterized and can be used as diagnostic markers, bile acids in tissues of these patients have not been well studied. It is important to gain insight into the accumulation of bile acids and their intermediates in tissues of patients because bile acid toxicity is postulated to play an important role in the underlying pathological mechanisms of these disorders, not only in liver but also in other organs such as the brain. For this reason, we analyzed bile acids by HPLC-negative ion electrospray tandem mass spectrometry (50, 51) in several tissues of patients with different peroxisomal disorders. The results of these analyses have not been published previously. We studied liver, brain, kidney, heart, spleen, lung, pancreas, and bile of patients with a peroxisome deficiency disorder (including patients with the severe Zellweger phenotype and patients with the milder neonatal adrenoleukodystrophy phenotype), patients with a deficiency of DBP (including patients with a DBP deficiency type I and type III) and one patient with an AMACR deficiency. The results of the bile acid measurements in liver are presented in Table 1 and Fig. 2A. The main accumulating bile acids in the liver of patients with a peroxisome deficiency disorder were t-THCA and THCA. Total C₂₅ bile acid intermediates were significantly increased and total C₂₄ bile acids significantly decreased compared with control livers. This resulted in clearly elevated C₂₅/C₂₄ bile acid ratios in all patient livers. The percentage of conjugated C₂₅ bile acid intermediates was only 51.5% compared with 96.4% for the C₂₄ bile acids. This shows that C₂₅ bile acid intermediates are poor substrates for the conjugating enzyme BAAT. The fact that the C₂₅ bile acids were almost fully conjugated (96.4% compared with 99% in control livers) suggests that BAAT could very well have a dual localization, not only in peroxisomes but also in the cytosol, or at least that BAAT is normally active and stable in the cytosol when peroxisomes are deficient. Both in the livers with a peroxisome deficiency and in the AMACR-deficient liver, the C₂₅ dicarboxylic acid (3α,7α,12α-trihydroxy-27-carboxymethyl-5β-cholestan-26-oic acid) was present, whereas it was not detected in DBP-deficient livers. In livers of patients with a DBP deficiency, the main accumulating C₂₅ bile acid intermediates were OH-THCA, t-THCA:1, and THCA, whereas those in the liver from the AMACR-deficient patient were t-THCA and THCA. The bile acid measurements showed that two DBP-deficient livers and the AMACR-deficient liver were cholestatic but this did not change the fact that the C₂₅/C₂₄ bile acid ratios were elevated in all patient livers. As in the peroxisome-deficient livers, the C₂₅ bile acid intermediates were partly conjugated, confirming that BAAT is poorly active with bile acids with an increased side chain length compared with C₂₄ bile acids (29, 52).

Bile of one patient with a peroxisome deficiency and the AMACR-deficient patient was analyzed in addition to the liver sample. For both patients, the C₂₅/C₂₄ bile acid ratio was higher in liver than in bile (2.58 vs. 1.66 in the peroxisome-deficient patient) and the percentage of conjugated C₂₅ bile acid intermediates was higher in bile than in liver (81% vs. 66% in the same patient). This suggests that C₂₅ bile acid intermediates are less efficiently transported across the canalicular membrane and that conju-
bile acid intermediates are the preferred substrates for this transport. At the moment, it is not known which transporters in the canalicular membrane are specifically involved in this process.

In the analyzed peripheral tissues (kidney, heart, spleen, lung, pancreas) of the different peroxisomal patients, the C27-bile acid intermediates clearly accumulated and the C27-bile acid intermediates of around 20-25% in the different tissues), the C27/C24-bile acid ratio was comparable to the one found in the liver (Fig. 2B). The pattern of accumulating metabolites was comparable to liver except that the main accumulating bile acids were THCA, DHCA, and OH-THCA, all unconjugated. In the brain, both C27- and C24-bile acid intermediates were detectable. The brains of DBP-deficient patients were much harder to distinguish from control brains based on the bile acid measurements. There were no significant differences for total C27-bile acid intermediates or C29-bile acids levels. The only bile acids that were elevated were OH-THCA and DHCA. For two patients with a peroxisome deficiency disorder, two DBP-deficient patients, and four control subjects, tissue from different brain areas was analyzed, including frontal white and gray matter, parietal white and gray matter, and extra frontal and parietal cortex. No significant difference between the bile acid content in the different brain areas was detected.

### Table 1. Bile acids in liver of control subjects, patients with a peroxisome deficiency disorder (PDD), and patients with a D-bifunctional protein (DBP) deficiency

| m/z | Controls | PDD | DBP | AMACR |
|-----|----------|-----|-----|------|
|     | n = 16   | n = 11 | n = 5 | n = 1 |
| C29DCA | 507 | 0.00 | 0.00-0.02 | 1.71** | 0.37-4.66 | 0.00 | 0.00-0.00 | 0.19 |
| t-OH-THCA | 573 | 0.03 | 0.00-0.14 | 2.99** | 0.54-9.78 | 1.48 | 0.00-5.35 | 1.28 |
| t-OH-THCA:1 | 570 | 0.03 | 0.00-0.53 | 0.96 | 0.00-0.29 | 3.45** | 0.02-8.78 | 0.37 |
| t-THCA | 556 | 0.36 | 0.05-2.26 | 26.51** | 4.54-95.43 | 4.80* | 0.38-19.61 | 74.14 |
| t-THCA:1 | 554 | 0.01 | 0.00-0.11 | 0.74** | 0.06-2.04 | 10.85** | 0.82-32.68 | 13.85 |
| t-DHCA | 555 | 0.02 | 0.00-0.08 | 3.40** | 0.39-8.87 | 0.53* | 0.05-2.22 | 4.66 |
| t-DHCA:1 | 553 | 0.01 | 0.00-0.17 | 0.10* | 0.00-0.47 | 1.32** | 0.19-4.56 | 0.13 |
| t-CA | 514 | 9.97 | 1.66-33.00 | 4.89 | 0.41-9.30 | 37.38* | 0.91-100.18 | 21.05 |
| t-UDCA | 498 | 0.30 | 0.00-1.17 | 0.04* | 0.00-0.15 | 0.92* | 0.00-1.90 | 1.90 |
| t-CDCA/DCA | 498 | 11.64 | 3.16-24.41 | 3.26** | 0.94-19.48 | 14.23 | 1.27-30.81 | 44.43 |
| g-THCA | 506 | 0.15 | 0.00-0.33 | 0.80** | 0.04-2.45 | 0.47* | 0.02-1.42 | 9.93 |
| g-CA | 464 | 10.08 | 1.45-41.30 | 3.67 | 0.39-10.01 | 37.08** | 2.31-96.25 | 52.96 |
| g-UDCA | 448 | 0.65 | 0.00-2.23 | 0.14* | 0.00-0.81 | 1.40 | 0.02-3.77 | 6.34 |
| g-CDCA/DCA | 448 | 18.47 | 2.00-48.30 | 4.26** | 0.86-18.07 | 20.62 | 1.26-48.68 | 74.16 |
| OH-THCA | 465 | 0.51 | 0.00-1.89 | 6.99** | 1.29-19.73 | 35.06* | 8.41-126.43 | 68.41 |
| OH-THCA:1 | 463 | 0.49 | 0.14-1.71 | 1.30** | 0.60-2.63 | 5.58** | 2.13-16.01 | 22.24 |
| THCA | 449 | 0.09 | 0.00-0.95 | 14.56** | 5.69-37.11 | 9.00** | 5.13-12.27 | 88.82 |
| THCA:1 | 447 | 0.36 | 0.00-0.62 | 1.76** | 0.70-4.04 | 6.13** | 2.76-13.87 | 10.54 |
| DHCA | 453 | 0.03 | 0.00-0.12 | 3.74** | 0.46-8.15 | 3.15** | 1.25-7.66 | 0.43 |
| DHCA:1 | 451 | 0.15 | 0.01-0.55 | 0.57** | 0.15-1.16 | 1.54 | 0.21-1.29 | 0.06 |
| CA | 407 | 0.41 | 0.07-2.22 | 0.29 | 0.14-0.75 | 1.99 | 0.31-7.78 | 4.89 |
| UDCA | 391 | 0.06 | 0.00-0.20 | 0.07 | 0.00-0.31 | 0.36 | 0.00-1.74 | 0.00 |
| CDCA/DCA | 391 | 0.07 | 0.01-0.21 | 0.12 | 0.05-0.30 | 0.93 | 0.03-4.09 | 9.07 |
| Total C27-BA | 2.04 | 0.53-7.67 | 63.52** | 18.54-178.36 | 83.96** | 32.37-252.15 | 294.86 |
| Total C24-BA | 51.97 | 15.46-80.62 | 16.74** | 6.38-34.40 | 121.66* | 9.89-317.55 | 216.46 |
| Total BA | 54.01 | 15.98-88.30 | 80.25** | 24.91-190.01 | 204.02** | 42.97-444.28 | 444.28 |
| C27/C24-BA ratio | 0.04 | 0.01-0.1 | 4.69** | 1.57-15.31 | 1.45** | 0.16-3.35 | 1.36 |

Bile acids are expressed as nmol/g wet weight. BA, bile acids. CDCA and DCA cannot be distinguished with the method used for bile acid measurement. * P < 0.05; ** P < 0.005 (t-test).

TOXICITY OF C27-BILE ACID INTERMEDIATES AND THE PATHOLOGICAL CONSEQUENCES OF A BILE ACID BIOSYNTHESIS DEFECT AT THE LEVEL OF THE PEROXISOME

The bile acid abnormalities in patients with a peroxisomal disorder have been shown to contribute to the liver disease associated with these disorders (53, 54) and also have been hypothesized to have an effect on the developing nervous system (55). The C27-bile acid intermediates are more hydrophobic than their C24-products, and as shown by the bile acid measurements in tissues of patients described above, they are less efficiently conjugated (augmenting to their hydrophobicity) and excreted into the bile. These factors will contribute to the retention of these intermediates in the liver, cholestasis, and, consequently, to hepatic injury in these patients. In addition, the primary bile acid deficiency decreases the intestinal dietary lipid...
ates are more cytotoxic than mature C_{24}-bile acids, with DHCA being clearly the most cytotoxic bile acid. In addition to the membrane-disruptive effects of bile acids due to their detergent properties, other mechanisms, like the induction of mitochondrial dysfunction, have been shown to be involved in the toxicity of bile acids (57). For this reason, the effect on the mitochondrial respiratory chain function was studied (56). It was shown that the different bile acids caused a dose-dependent decrease in ATP synthesis by isolated mitochondria oxidizing malate and glutamate (the order of potency of inhibition was: DHCA>THCA>CDCA>g-THCA>g-CDCA>t-THCA>CA). The unconjugated bile acids acted predominantly as uncouplers of the oxidative phosphorylation whereas the conjugated bile acids (t-THCA, g-THCA and g-CDCA) primarily inhibited the respiratory chain. By inhibiting the respiratory chain, the conjugated bile acids t-THCA, g-THCA, and g-CDCA enhanced reactive oxygen species (ROS) production at the level of complex III. Increased ROS generation leads to depletion of the antioxidants and can eventually lead to cell death. Interestingly, in the very first report describing Zellweger syndrome, brain and liver mitochondria from a patient showed strongly reduced respiration with malate and succinate as substrates (58). In addition, in a mouse model with hepatocyte-selective elimination of peroxisomes, severely reduced activities of complex I, III, and V were measured (59) and in a Pex5 knockout mouse, a model for Zellweger syndrome, reduction in the activities of complex I and V were observed (60), supporting the physiological relevance of the in vitro findings. The reduction of the activities of the respiratory chain complexes was accompanied by alterations of the mitochondrial inner membrane structure, which has also been observed in Zellweger patients (58, 61, 62).

Because the C_{27}-bile acid intermediates are especially cytotoxic, reducing their levels could be beneficial not only for the liver disease in peroxisomal patients but also to prevent potential injury to other organs by circulating C_{27}-bile acid intermediates. C_{27}-bile acid levels can be reduced by treatment with C_{24}-bile acids, which downregulate bile acid biosynthesis via activation of the nuclear receptor farnesoid X receptor (FXR), resulting in reduced transcriptional activation of CYP7A1, the rate-limiting enzyme in bile acid biosynthesis. In addition, bile acid therapy will increase bile flow by replenishing the decreased levels of C_{27}-bile acids and it will increase the intraluminal bile acid concentration, thereby facilitating the absorption of fats and fat soluble vitamins. Oral bile acid therapy has been tried with variable success in peroxisomal disorders (41, 63–65). The first report of such a bile acid treatment was in a 6-month-old Zellweger patient who showed significant improvement of biochemical indices of liver function and a histological improvement in the extent of inflammation and bile duct proliferation and disappearance of canalicular plugs (64). Steatorrhea improved and was accompanied by an improvement in growth. Plasma and urinary C_{27}-bile acid intermediates decreased with treatment. Despite the observed improvements, the patient died at one year of age. Also, in subsequent studies it has been
shown that patients with Zellweger syndrome are too severely affected by the multiple metabolic derangements for bile acid therapy to have a positive effect on the outcome of the disease (63, 65). However, in the Pex2 knockout mouse, another model for Zellweger syndrome, positive effects of bile acid therapy were observed (55, 66). Pex2 knockout mice were fed a mixture of CA and ursodeoxycholic acid (UDCA), which resulted in a significant improvement in postnatal survival. Increased body fat deposition was observed and improvement of the intestinal malabsorption. Compared with untreated mutant mice, bile acid treated Pex2 knockout mice were more active and less hypotonic but problems with balance and spasticity persisted. Interestingly, there was a significant improvement in some aspects of central nervous system development. In the liver, bile acid treatment alleviated intracellular cholestasis and prevented the development of severe steatohepatitis. However, the therapy exacerbated the degree of hepatic steatosis and worsened the already severe mitochondrial and cellular damage in the liver (66). These studies showed that peroxisome-deficient hepatocytes are particularly sensitive to bile acid toxicity, indicating that bile acid therapy will be more beneficial in patients with a relatively mild peroxisome biogenesis disorder (neonatal adrenoleukodystrophy or infantile Refsum disease) or patients with a single enzyme defect (AMACR, DBP, SCPx deficiency). Indeed, a child with AMACR deficiency has been reported to respond well to oral bile acid therapy for adrenoleukodystrophy or infantile Refsum disease (41). On treatment, the C_{27} bile acids intermediates are virtually absent in urine, her liver enzymes have remained normal, and her fat-soluble vitamins have remained normal without supplementation. As an alternative to oral bile acid therapy, treatment with an artificial FXR ligand should be considered. These artificial FXR ligands are not harmful for the hepatocyte but they downregulate the synthesis of the toxic C_{27} bile acid intermediates (67).

CONCLUDING REMARKS

The importance of proper peroxisomal function for the biosynthesis of bile acids has been firmly established. The peroxisomal enzymes involved in bile acid biosynthesis have all been identified. Only the transporters required for the transport of the C_{27}-bile acid intermediates into the peroxisome and for the conjugated C_{24}-bile acids out of the peroxisome remain unidentified. In addition, it is not clear yet whether deconjugated and recycled C_{24} bile acids need to reenter the peroxisome for reconjugation or whether this occurs in the cytosol. The bile acid abnormalities in patients with peroxisomal disorders have been well characterized and evidently play a role in the pathology of these disorders. The C_{24} bile acid intermediates have been shown to be more cytotoxic than the C_{27} bile acids, and the finding of primarily unconjugated C_{27} bile acid intermediates in brains from children with Zellweger syndrome suggests that the bile acid synthesis defect in these patients could also play a role in central nervous system pathology. Unfortunately, the clinical presentation of children with classical Zellweger syndrome is too severe due to the multiple metabolic derangements for a true positive effect of oral bile acid therapy in these patients but patients with a mild presentation (i.e., infantile Refsum disease) or a single enzyme deficiency could very well benefit from such a therapy or treatment with an FXR ligand to reduce the toxic C_{27} bile acid intermediates.

The authors thank Dr. Carl E. Clarke for providing patient material. Human tissue was obtained from the NICHD Brain and Tissue Bank for Developmental Disorders under contracts N01-HD-4-3368 and N01-HD-4-3383. We thank Henk Overmars for technical assistance.
REFERENCES

1. Russell, D. W. 2003. The enzymes, regulation, and genetics of bile acid synthesis. *Ann. Rev. Biochem.* 72: 137–174.

2. Mihalik, S. J., S. J. Steinberg, Z. Pei, J. Park, D. G. Kim, A. K. Heinzner, G. Dacremont, R. J. Wanders, D. A. Cuebas, K. D. Smith, and P. A. Watkins. 2002. Participation of two members of the very-long-chain acyl-CoA synthetase family in bile acid synthesis and recycling. *Biochim. Biophys. Acta.* **1505–15008.

3. Steinberg, S. J., S. J. Mihalik, D. G. Kim, D. A. Cuebas, and P. A. Watkins. 2000. The human liver-specific homolog of very-long-chain acyl-CoA synthetase is cholate-CoA ligase. *J. Biol. Chem.* **275:** 15605–15608.

4. Schepers, L., M. Castels, K. Verheyden, G. Parmentier, S. Asselberghs, H. J. Eysen, and G. P. Mannaerts. 1989. Subcellular distribution and characteristics of trihydroxycoprostanoyl-CoA synthetase in rat liver. *Biochem. J.* **257:** 221–229.

5. Schmitz, W., C. Albers, R. Fingerhut, and E. Conzelmann. 1995. Purification and characterization of an alpha-methylacyl-CoA racemase from human liver. *Eur. J. Biochem.* **231:** 815–822.

6. Schmitz, W., R. Fingerhut, and E. Conzelmann. 1994. Purification and properties of an alpha-methylacyl-CoA racemase from rat liver. *Eur. J. Biochem.* **222:** 513–523.

7. Pedersen, J. I., T. Veggan, and I. Bjorkhem. 1996. Substrate stereospecificity in oxidation of (25S)-alpha, 7 alpha, 12 alpha-trihydroxy-5 beta-cholestanoyl-CoA by peroxisomal trihydroxy-5 beta-cholestanoyl-CoA oxidase. *Biochem. Biophys. Res. Commun.* **224:** 37–42.

8. Visser, W. F., C. W. van Roermund, L. Ilijz, H. R. Waterham, and R. J. Wanders. 2007. Demonstration of bile acid transport across the mammalian peroxisomal membrane. *Biochem. Biophys. Res. Commun.* **357:** 335–340.

9. Kase, B. F., and I. Bjorkhem. 1989. Peroxisomal bile acid-CoA:aminocarboxylic acid-N-acetyltransferase in rat liver. *J. Biol. Chem.* **264:** 9220–9223.

10. Pellicoro, A., F. A. van den Heuvel, M. Geuken, H. Moshash, P. L. Jansen, and K. N. Faber. 2007. Human and rat bile acid-CoA:aminocarboxylic acid N-acetyltransferase are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport. *Hepatology.* **43:** 340–348.

11. O’Byrne, J., M. C. Hunt, D. K. Rai, M. Sacke, and S. E. Alexson. 2003. The human bile acid-CoA:aminocarboxylic acid N-acetyltransferase functions in the conjugation of fatty acids to glycine. *J. Biol. Chem.* **278:** 34237–34244.

12. Solaas, K., B. F. Kase, V. Pham, K. Bamberg, M. C. Hunt, and S. E. Alexson. 2004. Differential regulation of cytosolic and peroxisomal bile acid amidation by PPAR alpha activation favors the formation of conjugated bile acids. *J. Lipid Res.* **45:** 1024–1030.

13. Solaas, K., A. Ulvestad, O. Soreide, and B. F. Kase. 2000. Subcellular organization of bile acid amidation in human liver: a key issue in regulating the biosynthesis of bile salts. *J. Lipid Res.* **41:** 1154–1162.

14. Styles, N. A., J. L. Falany, S. Barnes, and C. N. Falany. 2007. Quantification and regulation of the subcellular distribution of bile acid coenzyme Aaminocarnitine acid N-acetyltransferase activity in rat liver. *J. Lipid Res.* **48:** 1305–1315.

15. Clayton, P. T. 1991. Inborn errors of bile acid metabolism. *J. Inherit. Metab. Dis.* **14:** 478–496.

16. van Eldere, J., R. G., G. Parmentier, H. J. Eysen, R. J. Wanders, R. B. Schugens, J. Vamecq, F. Van Hoof, B. T. Poll-The, and J. M. Sandrubra. 1987. Bile acids in peroxisomal disorders. *Eur. J. Clin. Invest.* **17:** 386–390.

17. Janssen, G., S. Toppet, and G. Parmentier. 1987. Structure of the side chain of the C29 diacarboxylic bile acid occurring in infants with coprostaneic acidemia. *J. Lipid Res.* **28:** 456–465.

18. Patron, G. A. G., G. A. Janssen, E. A. Eggermont, and H. J. Eysen. 1979. C27 bile acids in infants with coprostaneic acidemia and occurrence of a 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-C29 diacarboxylic bile acid as a major component in their serum. *Eur. J. Biochem.* **102:** 173–183.

19. Lawson, A. M., M. J. Madigan, D. Shortland, and P. T. Clayton. 1986. Rapid diagnosis of Zellweger syndrome and infantile Refsum’s disease by fast atom bombardment–mass spectrometry of urine bile salts. *Clin. Chim. Acta.* **161:** 221–231.

20. Ume, M. Y., T. Tazawa, K. Tada, and T. Hoshiba. 1987. Occurrence of both (25R)- and (25S)-3 alpha,7 alpha,12 alpha-trihydroxy-5

2146 Journal of Lipid Research Volume 50, 2009
beta-cholestanolic acids in urine from an infant with Zellweger’s syndrome. *J. Biochem. (Tokyo)*. **102**:1525–1530.

39. Yousef, I. M., S. Perwaiz, T. Lamireau, and B. Tuchweber. 2003. Urinary bile acid profile in children with inborn errors of bile acid metabolism and chronic cholestasis; screening technique using electrospray tandem mass-spectrometry (ES/MS/MS). *Med. Sci. Monit.* **9**:MT21–MT31.

40. Ferdinandusse, S., H. Overmars, S. Denis, H. R. Waterham, R. J. A. Wanders, and P. Vreken. 2001. Plasma analysis of di- and trihydroxycholestanolic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency. *J. Lipid Res.* **42**:137–141.

41. Setchell, K. D., J. E. Heubi, K. E. Bove, N. C. O’Connell, T. Brewsaugh, S. J. Steinberg, A. Moser, and R. H. Squires, Jr. 2003. Liver disease caused by failure to racemize trihydroxycholestanolic acid: gene mutation and effect of bile acid therapy. *Gastroenterology*. **124**:217–232.

42. van Veldhoven, P. P., G. Vanhove, S. Assselberghs, H. J. Eyssen, and G. P. Manns. 1992. Substrate specificities of rat liver peroxisomal acyl-CoA oxidases: palmitoyl-CoA oxidase (inducible acyl-CoA oxidase), pristanoyl-CoA oxidase (non-inducible acyl-CoA oxidase), and trihydroxypropanoyl-CoA oxidase. *J. Biol. Chem.* **267**:20065–20074.

43. Wanders, R. J. S., and G. Decremont. 1993. Studies on the substrate specificity of the inducible and non-inducible acyl-CoA oxidases from rat kidney peroxisomes. *J. Biochem. (Tokyo)*. **115**:577–582.

44. Ferdinandusse, S., S. Denis, E. M. Hogenhout, J. Koster, C. W. van Roermund, L. Jb, A. B. Moser, R. J. Wanders, and H. R. Waterham. 2007. Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency. *Hum. Mutat.* **28**:904–912.

45. Une, M., M. Konishi, Y. Suzuki, S. Akaboshi, M. Yoshii, T. Kuramata, and K. Fujimura. 1997. Bile acid profiles in a peroxisomal D-3-hydroxyacyl-CoA dehydrogenase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein deficiency. *J. Biochem. (Tokyo)*. **122**:655–658.

46. Vreken, P., A. van Rooij, S. Denis, E. G. van Gruunsw, D. A. Cuebas, and R. J. Wanders. 1999. Sensitive analysis of serum 3alpha, 7alpha, 12alpha,24-tetrahydroxy-5beta-cholestan-26-oic acid diastereomers using gas chromatography-mass spectrometry and its application in peroxisomal D-bifunctional protein deficiency. *J. Lipid Res.* **39**:2452–2458.

47. Cuebas, D. A., C. Phillips, W. Schmitz, E. Conzelmann, and D. K. Novikos. 2002. The role of alpha-methylacyl-CoA racemase in bile acid synthesis. *Biochem. J.* **363**:801–807.

48. Ferdinandusse, S., S. Denis, P. A. Mooover, C. Dekker, M. Duran, R. J. Soorani-Lunsing, E. Bolshauer, A. Macaya, J. Gartner, C. B. Majoe, et al. 2006. Clinical and biochemical spectrum of D-bifunctional protein deficiency. *Ann. Neurol.* **59**:92–104.

49. Ferdinandusse, S., P. Kostopoulos, S. Denis, H. Rusch, H. Overmars, U. Dillmann, W. Reith, D. Haas, R. J. A. Wanders, M. Duran, et al. 2006. Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukencephalopathy with dystonia and motor neuropathy. *Am. J. Hum. Genet.* **78**:1046–1052.

50. Bootisma, A. H., H. Overmars, A. van Rooij, D. E. van Lint, R. J. Wanders, A. H. van Gennip, and P. Vreken. 1999. Rapid analysis of conjugated bile acids in plasma using electrospray tandem mass spectrometry: application for selective screening of peroxisomal disorders. *J. Inherit. Metab. Dis.* **22**:307–310.

51. Ferdinandusse, S., S. Denis, H. Overmars, L. Van Eckhoudt, P. P. Van Veldhoven, M. Duran, R. J. Wanders, and M. Baes. 2005. Developmental changes of bile acid composition and conjugation in L- and D-bifunctional protein single and double knockout mice. *J. Biol. Chem.* **280**:18658–18666.

52. Gubu, B., and D. A. Vessey. 1982. The effect of bile acid structure on the activity of bile acid-CoA/glycerine/taurine-N-acetyltransferase. *J. Biol. Chem.* **257**:8761–8765.

53. Bove, K. E., C. C. Daugherty, W. Tyson, G. Mierau, J. E. Heubi, W. F. Balisteri, and K. D. Setchell. 2000. Bile acid synthetic defects and liver disease. *Pediatr. Dev. Pathol.* **3**:1–16.

54. Sundaram, S. S., K. E. Bove, M. A. Lovell, and R. J. Sokol. 2008. Mechanisms of disease: inborn errors of bile acid synthesis. *Nat. Clin. Pract. Gastroenterol. Hepatol.* **5**:456–468.

55. Faust, P. L., D. Banka, R. Siriratsiwong, V. G. Ng, and T. M. Wikander. 2005. Peroxisome biogenesis disorders: the role of peroxisomes and metabolic dysfunction in developing brain. *J. Inherit. Metab. Dis.* **28**:369–383.

56. Ferdinandusse, S., S. Denis, G. Decremont, and R. J. Wanders. 2009. Toxicity of peroxisomal C27-bile acid intermediates. *Med. Genet. Metab.* **96**:121–128.

57. Palmeira, C. M., and A. P. Rolo. 2004. Mitochondrially-mediated toxicity of bile acids. *Toxicology*. **203**:1–15.

58. Goldfischer, S., C. L. Moore, A. B. Johnson, A. J. Spiro, M. P. Valsamis, H. K. Wisniewski, R. H. Ritch, W. T. Norton, I. Rapin, and L. M. Gartner. 1973. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. *Science*. **182**:62–64.

59. Dirxx, R., J. Vanhorebeek, K. Martens, A. Schad, M. Grabenbauer, D. Fahimi, P. Declercq, P. P. Van Veldhoven, and M. Baes. 2005. Absence of peroxisomes in mouse hepatocytes causes mitochondrial and ER abnormalities. *Hepatology*. **41**:868–876.

60. Baumgurt, E., I. Vanhorebeek, M. Grabenbauer, M. Borgers, P. E. Declercq, H. D. Fahimi, and M. Baes. 2001. Mitochondrial alterations caused by defective peroxisomal biogenesis in a mouse model for Zellweger syndrome (PEX5 knockout mouse). *Am. J. Pathol.* **159**:1477–1494.

61. Hughes, J. L., A. Poulos, E. Robertson, C. W. Chow, L. J. Sheffield, J. Christodoulou, and R. F. Carter. 1990. Pathology of hepatic peroxisomes and mitochondria in patients with peroxisomal disorders. *Virchows Arch. A Pathol. Anat. Histopathol.* **416**:233–264.

62. Mathis, R. K., J. B. Watkins, P. Szczepanik-Van Leeuwen, and I. T. Lott. 1980. Liver in the cerebro-hepato-renal syndrome: defective bile acid synthesis and abnormal mitochondria. *Gastroenterology*. **79**:1311–1317.

63. Maeda, K., A. Kimura, Y. Yamato, H. Nittomo, H. Takei, T. Sato, H. Mittsuchi, T. Murai, and T. Kurosawa. 2002. Oral bile acid treatment in two Japanese patients with Zellweger syndrome. *J. Pediatr. Gastroenterol. Nutr.* **35**:227–230.

64. Setchell, K. D., P. Bragetti, L. Zimmer-Nechimias, C. Daugherty, M. A. Pelli, R. Vaccaro, G. Gentili, E. Distritti, G. Duzzini, A. Morelli, et al. 1992. Oral bile acid treatment and the patient with Zellweger syndrome. *Hepatology*. **15**:198–207.

65. Setchell, K. D., and J. E. Heubi. 2006. Defects in bile acid biosynthesis–diagnosis and treatment. *J. Pediatr. Gastroenterol. Nutr.* **43**(Suppl 1):S17–S22.

66. Keane, M. H., H. Overmars, T. M. Wikander, S. Ferdinandusse, M. Duran, R. J. Wanders, and P. L. Faust. 2007. Bile acid treatment alters hepatic disease and bile acid transport in peroxisome-deficient PEX2 Zellweger mice. *Hepatology*. **43**:982–997.

67. Liu, Y., J. Binz, M. J. Nemerick, S. Dennis, G. Luo, B. Desai, K. I. Mackenzie, T. A. Mansfield, S. A. Kliwer, B. Goodwin, et al. 2003. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. *J. Clin. Invest.* **112**:1678–1687.